Women with transthyretin amyloid cardiomyopathy (ATTR-CM) had worse outcomes than men in a new study, but the gap may…
Articles by Marisa Horak, MS
A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who…
The injectable therapy eplontersen failed to show a significant benefit over a placebo at reducing cardiovascular events and related…
Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with…
In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute…
Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in…
New analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial treatment for people with…
The injection therapy Wainua (eplontersen) “offers a vital ray of hope” for people living with hereditary transthyretin amyloidosis…
New analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart failure, with differences seen within 30…
People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in…